New findings provide insights about how the intestine maximizes nutrient uptake, while at the same time protecting the body from potentially dangerous microbes.
Rockefeller scientists have identified a genetic condition that makes people prone to developing tuberculosis. In a British population, they found that the condition underlies one percent of cases of the disease—a finding that may ultimately lead to new treatment options.
Researchers successfully modified immune cells to produce antibodies that fight HIV. This strategy could eventually be used to develop a vaccine against the virus, among other conditions.
Increasingly, bacteria do not succumb to antibiotics. Rockefeller researchers have developed a new class of antimicrobial drug, lysin, with one compound showing promising results in a clinical trial—suggesting that an alternative to antibiotics may be on the horizon.
Geckos are amazingly agile. In addition to running across land and up trees, the animals can prance across the surface of water. A new study reveals how they do it.
Using gene editing technology, researchers have developed a new way to study B cell activation in mice. This technique makes research more efficient, and has the potential to improve our understanding of immune responses in humans.
Researchers have uncovered the genetic factors that make some people susceptible to Whipple's disease, an intestinal inflammatory disorder that causes diarrhea, pain, and weight loss.
Maimon, who studies cognition and decision-making, and Marraffini, who studies the bacterial defense system CRISPR-Cas, are among 19 scientists nationwide to receive this designation.
Ravetch receives the award for his groundbreaking work analyzing the immune system’s antibody response. He has worked for decades on the Fc fragment of the antibody molecule and its binding partners, known as Fc receptors.
